Closing Panel Discussion: Future Directions for BCMA-Directed Therapies

Time: 3:00 pm


  • Pricing/Cost
  • Accessibility changes
  • Is improved trial design needed?
  • How will they be commercialized?
  • What is the ultimate limit of BCMA as a target for myeloma?
  • How will cell therapy infrastructure evolve & how will this effect current situation?
  • Potential limitations to BCMA and how other targets (FcRb5/FcR115, NC28, CS1, SIRH5) could fit in the future clinical landscape
  • Long-term outlook